Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
How would you approach chronic isolated severe non-cyclic neutropenia with negative bone marrow and rheumatologic work-up?
My preference would be to use G-CSF at the lowest effective dose, i.e., the dose that maintains the ANC >1000. The risk of inducing leukemia is low in individuals with idiopathic, chronic neutropenia, but it is positively correlated with the G-CSF dose. There are also other side effects like bone pa...
What further genetic testing would you perform on a pediatric patient with cyclic neutropenia who is negative for the most common associated mutations?
Virtually all autosomal dominant cyclic neutropenia is due to mutation in the ELANE gene. However, all neutropenia that varies over time is not necessarily hereditary cyclic neutropenia, even though the family history suggests so. It would be helpful to know if the family history follows an AD inher...
With new data showing similar outcomes of mismatched unrelated donor and haploidentical related donor allogeneic transplants using post transplant cyclophosphamide, how does one decide which donor is optimal?
It is certainly an unresolved question, and the short answer is that either would be an acceptable option with post-transplant cyclophosphamide (and I have used both). All recipients of mismatched donor transplants should be tested for the presence of donor specific antibodies, and their presence co...
How do you approach evaluation of pulmonary vein thrombosis?
Pulmonary vein thrombosis is a rare condition that is usually associated with injury to the vessel, for example after surgery or lung transplantation, or as a complication of lung cancer. I am not aware of any data on the relative efficacy of different anticoagulants in PVT but from a biologic persp...
Would you consider bone marrow transplant in a pediatric patient with recurrent HLH with no identified exogenous trigger or HLH-associated mutation?
What factors besides disease progression would lead you to de-intensify or change MM therapy for a patient with ongoing response?
After initial therapy (which may or may not include an autologous stem cell transplant), patients are generally on continuous/maintenance therapy with e.g. lenalidomide as the most common regimen. Most patients do well on this as maintenance. However, loose stools are probably the most common compla...
How do you counsel patients with newly diagnosed transplant-ineligible multiple myeloma on the expectations of treatment in terms of disease control, duration of therapy, monitoring and follow up?
I'm going to take this question very literally and write a paraphrase of my general explanation to patients at an initial diagnosis and treatment planning visit. Forgive me, this is long, a paraphrase of a 30-60 minute visit with a patient. I hope this will result in others sharing how they navigate...
When do you consider re-treatment with lenalidomide in later line therapy for relapsed multiple myeloma?
It is a challenging question due to the fact all studies post lenalidomide failure even in maintenance never included lenalidomide based therapy in first up to third line of therapy: such as Dara/Pom/dex, Dara/Car/dec, Elo/Pom/dex, Pom/Vel/dex … some argue that since the patient was on low dose of l...
Do you routinely obtain bone marrow biopsy in newly diagnosed autoimmune hemolytic anemia when working up potential underlying etiologies?
Thank you for the question. For patients with cold agglutin disease, I perform a bone marrow biopsy and flow cytometry at diagnosis/before initiating therapy on all patients. I base the decision whether to do a bone marrow biopsy after initial diagnosis of warm autoimmune hemolytic anemia based on w...
How does evidence of cerebral amyloid angiopathy/microbleeds affect choices for secondary stroke prevention in patients with a history of ischemic stroke and atrial fibrillation?
This is a discussion I have with the patient, mentioning that the positive predictive value of cortically based cerebral microhemorrhages is not absolute, especially when there is a small number of them and there are no other signs of small vessel disease (such as FLAIR changes or enlarged peri-vasc...